Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL2

CCL2

Basics

Aliases:
This biomarker is also known as:
  • Monocyte secretory protein JE,
  • monocyte secretory protein JE,
  • small-inducible cytokine A2,
  • MCP1,
  • monocyte chemoattractant protein-1,
  • small inducible cytokine subfamily A (Cys-Cys), member 2,
  • GDCF-2,
  • monocyte chemotactic and activating factor,
  • MCAF,
  • HSMCR30,
  • HC11,
  • monocyte chemotactic protein 1,
  • chemokine (C-C motif) ligand 2,
  • Monocyte chemotactic protein 1,
  • small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
  • Small-inducible cytokine A2,
  • SMC-CF,
  • SCYA2,
  • Monocyte chemotactic and activating factor,
  • C-C motif chemokine 2,
  • Monocyte chemoattractant protein 1,
  • MGC9434,
  • monocyte chemoattractant protein 1,
  • MCP-1,

View in BioMuta

Description…

CCL2, also known as MCP-1, is a member of the chemokine superfamily. Chemokines are a family of small cytokines. The four chemokine subfamilies are based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2 is a member of the CC subfamily, characterized by two adjacent cysteine residues. CCL2 is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.